UA78676C2 - Purified lh - Google Patents

Purified lh

Info

Publication number
UA78676C2
UA78676C2 UA2002086889A UA2002086889A UA78676C2 UA 78676 C2 UA78676 C2 UA 78676C2 UA 2002086889 A UA2002086889 A UA 2002086889A UA 2002086889 A UA2002086889 A UA 2002086889A UA 78676 C2 UA78676 C2 UA 78676C2
Authority
UA
Ukraine
Prior art keywords
purification
ion
reverse phase
phase hplc
recombinant human
Prior art date
Application number
UA2002086889A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of UA78676C2 publication Critical patent/UA78676C2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA2002086889A 2000-02-22 2001-01-22 Purified lh UA78676C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00103692 2000-02-22
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh

Publications (1)

Publication Number Publication Date
UA78676C2 true UA78676C2 (en) 2007-04-25

Family

ID=8167926

Family Applications (2)

Application Number Title Priority Date Filing Date
UA2002086889A UA78676C2 (en) 2000-02-22 2001-01-22 Purified lh
UAA200612399A UA92145C2 (en) 2000-02-22 2001-01-22 Purified lh

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200612399A UA92145C2 (en) 2000-02-22 2001-01-22 Purified lh

Country Status (30)

Country Link
US (2) US7053054B2 (cs)
EP (2) EP1261622B1 (cs)
JP (1) JP4959898B2 (cs)
KR (1) KR100808149B1 (cs)
CN (1) CN100480258C (cs)
AT (1) ATE356138T1 (cs)
AU (1) AU780377B2 (cs)
BG (1) BG65761B1 (cs)
BR (2) BRPI0108553B8 (cs)
CA (1) CA2399100C (cs)
CY (1) CY1108056T1 (cs)
CZ (1) CZ303274B6 (cs)
DE (1) DE60127100T2 (cs)
DK (1) DK1261622T3 (cs)
EA (1) EA004385B1 (cs)
EE (1) EE04932B1 (cs)
ES (1) ES2278722T3 (cs)
HR (1) HRP20020651B1 (cs)
HU (1) HU227007B1 (cs)
IL (2) IL151309A0 (cs)
MX (1) MXPA02007867A (cs)
NO (1) NO328693B1 (cs)
PL (1) PL207728B1 (cs)
PT (1) PT1261622E (cs)
RS (1) RS50416B (cs)
SI (1) SI1261622T1 (cs)
SK (1) SK287041B6 (cs)
UA (2) UA78676C2 (cs)
WO (1) WO2001062774A2 (cs)
ZA (1) ZA200206108B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278722T3 (es) * 2000-02-22 2007-08-16 Applied Research Systems Ars Holding N.V. Hlh purificada recombinante que tiene una bioactividad especifica y procedimiento para su purificacion.
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
NZ542549A (en) * 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
JP4763616B2 (ja) * 2003-12-22 2011-08-31 アレス トレーディング ソシエテ アノニム Ｆｓｈを精製するための方法
EP1709065B1 (en) * 2004-10-04 2010-06-02 Novetide Ltd. A counterion exchange process for peptides
DE602005009856D1 (de) * 2004-11-09 2008-10-30 Ares Trading Sa Verfahren zur reinigung von fsh
WO2007022799A1 (en) * 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
AU2006323925B2 (en) 2005-12-09 2012-08-02 Ares Trading S.A. Method for purifying FSH or a FSH mutant
EP2203465A1 (en) * 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying an fc-containing protein
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
WO2015168622A1 (en) * 2014-05-01 2015-11-05 Virginia Tech Intellectual Properties, Inc. Keratin nanomaterials and methods of production
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
DK0461200T3 (da) * 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ATE439439T1 (de) 1997-06-25 2009-08-15 Merck Serono Sa Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
ES2278722T3 (es) * 2000-02-22 2007-08-16 Applied Research Systems Ars Holding N.V. Hlh purificada recombinante que tiene una bioactividad especifica y procedimiento para su purificacion.

Also Published As

Publication number Publication date
ATE356138T1 (de) 2007-03-15
NO328693B1 (no) 2010-04-26
BG107001A (bg) 2003-04-30
EA200200893A1 (ru) 2003-02-27
DE60127100T2 (de) 2007-06-28
RS50416B (sr) 2009-12-31
NO20023963D0 (no) 2002-08-20
BR122012018280B1 (pt) 2018-01-09
CN100480258C (zh) 2009-04-22
SK12052002A3 (sk) 2002-12-03
CA2399100A1 (en) 2001-08-30
ES2278722T3 (es) 2007-08-16
BR122012018280B8 (pt) 2021-05-25
WO2001062774A2 (en) 2001-08-30
EP1261622A2 (en) 2002-12-04
EP1777231A2 (en) 2007-04-25
JP2003532636A (ja) 2003-11-05
HU227007B1 (en) 2010-04-28
DK1261622T3 (da) 2007-05-29
US20030186893A1 (en) 2003-10-02
BG65761B1 (bg) 2009-10-30
BRPI0108553B1 (pt) 2016-06-14
AU780377B2 (en) 2005-03-17
CZ303274B6 (cs) 2012-07-11
DE60127100D1 (de) 2007-04-19
EA004385B1 (ru) 2004-04-29
PL207728B1 (pl) 2011-01-31
CA2399100C (en) 2011-11-08
HUP0301814A2 (hu) 2003-08-28
KR20030001358A (ko) 2003-01-06
SI1261622T1 (sl) 2007-06-30
IL151309A (en) 2010-11-30
CY1108056T1 (el) 2013-09-04
YU60302A (sh) 2005-09-19
PL362891A1 (en) 2004-11-02
US20060079460A1 (en) 2006-04-13
SK287041B6 (sk) 2009-10-07
WO2001062774A3 (en) 2002-03-14
EE200200464A (et) 2003-12-15
BRPI0108553B8 (pt) 2021-05-25
ZA200206108B (en) 2003-07-31
PT1261622E (pt) 2007-04-30
CN1404486A (zh) 2003-03-19
NO20023963L (no) 2002-08-20
HRP20020651A2 (en) 2004-12-31
EP1777231A3 (en) 2007-11-07
HUP0301814A3 (en) 2004-10-28
HRP20020651B1 (en) 2011-01-31
EE04932B1 (et) 2007-12-17
JP4959898B2 (ja) 2012-06-27
AU3543601A (en) 2001-09-03
BR0108553A (pt) 2003-12-23
IL151309A0 (en) 2003-04-10
KR100808149B1 (ko) 2008-02-29
EP1261622B1 (en) 2007-03-07
MXPA02007867A (es) 2003-02-10
CZ20022856A3 (cs) 2003-01-15
HK1052014A1 (zh) 2003-08-29
US7053054B2 (en) 2006-05-30
UA92145C2 (en) 2010-10-11

Similar Documents

Publication Publication Date Title
UA78676C2 (en) Purified lh
BG107000A (en) PROCESS OF PURIFICATION OF hCG AND RECOMBINANT hCG PURIFIED BY THAT METHOD
ITRM910788A1 (it) Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
MXPA01010522A (es) Composiciones de gonadotropina altamente purificada y procedimiento para prepararlas.
ES2161790T3 (es) Procedimiento de separacion y de purificacion de proteinas dependientes de la vitamina k.
Hocart et al. Improved antagonists of luteinizing hormone-releasing hormone modified in position 7
PL1697411T3 (pl) Sposób oczyszczania interferonu beta
Arnold et al. Improved solid-phase synthesis of the luteinizing-hormone releasing-hormone/follicle-stimulating hormone releasing-hormone (LH-RH/FSH-RH)
IT1245230B (it) Procedimento di preparazione della timopentina
Bataille et al. Isolation and chemical characterization of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum
UA29025A (uk) Спосіб лікування ендокринної неплідності